Monday, 24 Feb 2020

Biologic/Novel Rx

Date Typesort ascending Title Save
28 Dec 2017 Social This is the single best source on Biologics for Patients - Download the Patient Guide to Biologics from RheumNow. 6 pages of overview/comparisons; 5 biologic handouts
21 Aug 2017 Social Ironwood announces FDA approval of its combo drug lesinurad/allopurinol in a 200/300 tablet. Could this be useful?
09 Nov 2018 Social Frankincense is derived from Boswellia plants. Boswellia serrata is an Ayurvedic purported to be anti-inflammatory; inhibits 5-lipoxygenase & possibly prostaglandins, Pilot studies in OA have shown significant pain relief and improved physical function
09 Aug 2019 Social Amgen wins U.S. patent battle against Novartis over Enbrel patents, delaying Novartis' attempts to launch its etanercept biosimilar Erelzi until (possibly) 2029. Novartis intends to appeal.
12 Apr 2017 Social Looking for PATIENT Views on BIOSIMILAR BIOLOGIC Drugs - They're new, how will they affect you. Patients vote at>>
29 Mar 2018 Social Large BSRBR study of Serious infections w/ biologics shows SI=5.51 per 100PY for all; tocilizumab was higher vs ETN (HR 1.22; 1.02 to 1.47) & certolizumab lower or equal to ETN. 30-day mortality following SI was 10.4% (95% CI 9.2% to 11.6%).
20 Mar 2016 Social Tofacitinib meets primary endpoints in ulcerative colitis trials, achieving 16-18% remission rates
29 Nov 2016 Social Good, basic overview of Biosimilars.
03 May 2018 Social Sandoz biosimilar version of rituximab set back by a complete response letter from the FDA delaying development of their RTX biosimilar; same recent fate as Celltrions RTX biosimilar.
20 Oct 2017 Social RT @emartinmola: High ‘nocebo’ effect observed when patients knowingly switch to a biosimilar
14 Dec 2016 Social IL-33 a biomarker for RTX response - if RA pts are RF+ or CCP+; w/ detectable serum IL-33 & High IgG levels.
12 Nov 2019 Social RT @philipcrobinson: Yes, you read that right US$5,000,000,000 increase in biological DMARD spending #ACR19 @RheumNow Abs 2731…
11 Dec 2019 Social Biosimilar Tote-Board in Rheumatology: 4 Infliximab biosimilars - Inflectra, Renflexis, Ifixi, Avsola 5 Adalimumab biosimilars - Amjevita, Cyltezo, Hyrimoz, Hadlima, Abrilada 2 Etanercept biosimilars - Erelzi, Enticovo 2 Rituximab biosimilars - Truxima, Ruxience
05 May 2017 Social Japan Study shows 8mg IV Actemra can be escalated to q3 wks IV or reduced to q5 wks IV according to q4wk response
13 Jun 2018 Social RT @FerreiraRJO: Excellent talk from Tracy French about how nurses can promote shared decision making with patients being proposed to switc…
07 Nov 2017 Social RT @DrPetryna: #16L #acr17 no risk of DVTorPE w/Tofa from RTC trials analysis. IRs comparable to #corona data for Tofa&cDMARDs @RheumNow ht…
06 Jun 2016 Social Did you know that many (not all) biologics have latex? Dr. Dao writes how to Handle Latex Allergies w/ Biologics
13 Feb 2020 Social RT @Janetbirdope: Adalimumab seeems better than infliximab Behcet’s uveitis. Alvin Wells #RWCS2020 @RheumNow
22 Jul 2016 Social In Tofacitinib RCTs 1821 child-bearing age F exposed; 47 pregnant (33 monoRx). 1 Pulm valve stenosis, 7 Spont Abs.
14 Sep 2018 Social FDA approves SC Actemra (tocilizumab) for systemic JIA (Still's disease) +/-MTX. IV TCZ was FDA approved In 2011 for SJIA. Approval is based on JIGSAW, a 52-wk study. sJIA dosing based on Weight ( <30 kg-162 mg q2wk; ≥30 162 mg qwk)